News

New listing of SCOPE FLUIDICS

The company SCOPE FLUIDICS S.A. was newly listed on the GPW Main Market on 20 January 2023.
SCOPE FLUIDICS S.A. is the 418^th company listed on the Main Market and the third new listing on the Main Market in 2023.

Key information

* based on the average price of the Company’s shares in the NC ATS for the last 3 months preceding the date of the application for admission, equal to PLN 202.73

Issuer’s history and business

The Company’s shares were listed in the NewConnect Alternative Trading System from 16 August 2017.

The legal predecessor of the Issuer, Scope Fluidics Sp. z o.o., was established in 2010. The Issuer has been operating as a joint-stock company since March 2017.
The Issuer’s core business is the development of technology projects in the field of diagnostics and healthcare. The Company’s business concept is to implement innovative projects through special purpose vehicles which are controlled by the Company in order to sell them to a global entity. Project implementation begins with the Company identifying needs in the area of life science that can be addressed using microfluidic technologies. An innovative solution is then developed; starting with the decision to launch the project, it is subject to continuous technological and business validation. The initial concept of a new solution is developed within the Company and then a special purpose vehicle is established for the further development and implementation of the new concept. Funds are transferred to subsidiaries through capital increases and the granting of loans. The Issuer handles all matters related to raising funding for the subsidiaries and is responsible for supporting project managers in project management. As at the Prospectus Date, the Company has eight employees.

PCR|ONE project

Within its subsidiary Curiosity Diagnostics Sp. z o.o., the Issuer conducted research and development of molecular diagnostic methods using PCR technology for the rapid diagnosis of diseases caused by bacterial and viral agents. On 2 August 2022, the Issuer entered into an agreement to sell 100% of Curiosity Diagnostics to Bio-Rad Laboratories, Inc., a global market player in the medical diagnostics sector. As agreed by the Parties, the Company received a total of USD 100 million for the divestment and may receive up to USD 70 million depending on additional milestones set out in the agreement.

Bacteromic project

The Issuer’s subsidiary Bacteromic sp. z o.o. is currently developing a system to test antibiotic resistance in bacteria. BacterOMIC combines classic drug susceptibility assessment methodology with innovative microfluidic technology to acquire a wide range of clinically relevant information in a single test. BacterOMIC has the potential to assess the drug susceptibility of microorganisms against all key clinically used antibiotics in a single test. This will allow early initiation of effective antibiotic therapy for patients and reduce the duration of hospitalisation. As at the Prospectus Date, Bacteromic sp. z o.o. has 22 employees.

Third project

In 2020, the Management Board decided to select a new project involving the development of a system using microfluidic technology to automatically test the microbiological safety of products for the FMCG (Fast Moving Consumer Goods) industry. Until August 2022, the Group focused on the development and commercialisation of the PCR|ONE system and on the development and preparation for the commercialisation of the BacterOMIC system; consequently, the Company did not make significant progress in the development of the third project.

Issuer's share capital

The Issuer's share capital according to a copy of its entry in the National Court Register amounts to PLN 272,593 and is divided into 2,725,930 ordinary bearer shares with a nominal value of PLN 0.1 each, including:

• 101,107 series A ordinary bearer shares;
• 1,268,893 series B ordinary bearer shares;
• 900,000 series C ordinary bearer shares;
• 34,050 series D ordinary bearer shares;
• 11,350 series E ordinary bearer shares;
• 231,540 series F ordinary bearer shares;
• 11,350 series G ordinary bearer shares;
• 127,915 series H ordinary bearer shares;
• 39,725 series J registered shares.

All shares of the Issuer, with the exception of series J shares, are traded on NewConnect.

The Issuer did not conduct a public offering in connection with its new listing on the GPW Main Market.

Issuer’s selected consolidated financials:

The Company did not publish financial forecasts.

Newly listed instruments:

• 101,107 series A ordinary bearer shares;
• 1,268,893 series B ordinary bearer shares;
• 900,000 series C ordinary bearer shares;
• 34,050 series D ordinary bearer shares;
• 11,350 series E ordinary bearer shares;
• 231,540 series F ordinary bearer shares;
• 11,350 series G ordinary bearer shares;
• 127,915 series H ordinary bearer shares.